回盛生物
(300871)
| 流通市值：33.46亿 | | | 总市值：33.46亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 262,866,552.55 | 358,774,731.38 | 398,320,915.73 | 310,196,815.8 |
| 交易性金融资产 | 213,968,055.15 | 214,410,068.74 | 211,932,540.6 | 160,332,278.92 |
| 应收票据及应收账款 | 501,181,912.26 | 474,268,758.87 | 488,673,372.29 | 449,406,641.92 |
| 其中：应收票据 | 79,836,918.58 | 56,588,048.76 | 46,531,559.35 | 54,629,769.94 |
| 应收账款 | 421,344,993.68 | 417,680,710.11 | 442,141,812.94 | 394,776,871.98 |
| 应收款项融资 | 23,614,706.3 | 80,656,232.93 | 50,488,932.21 | 6,912,964.8 |
| 预付款项 | 42,029,176.78 | 26,741,773.18 | 49,371,118.24 | 86,603,833.16 |
| 其他应收款合计 | 7,739,782.48 | 78,598,841.73 | 17,353,690.06 | 17,745,546.27 |
| 存货 | 311,083,186.03 | 285,436,235.23 | 275,556,576.2 | 267,889,272.32 |
| 其他流动资产 | 36,756,007.24 | 23,081,962.47 | 7,228,760.45 | 7,839,216.67 |
| 流动资产合计 | 1,399,239,378.79 | 1,541,968,604.53 | 1,498,925,905.78 | 1,306,926,569.86 |
| 非流动资产: | | | | |
| 长期股权投资 | 31,668,864.74 | 31,433,086.48 | 1,401,421.1 | - |
| 投资性房地产 | 20,636,778.45 | 14,606,177.15 | 14,605,650.06 | 13,036,421.44 |
| 固定资产 | 1,472,069,008.99 | 1,490,903,295.74 | 1,533,396,313.8 | 1,492,353,671.21 |
| 在建工程 | 314,048,307.9 | 158,433,976.38 | 3,880,996.64 | 58,932,814.2 |
| 无形资产 | 114,038,585.32 | 114,861,091.6 | 109,543,826.07 | 110,566,789.91 |
| 商誉 | 522,332.26 | 522,332.26 | 522,332.26 | 522,332.26 |
| 长期待摊费用 | 1,130,422.16 | 768,515.78 | 857,190.68 | 945,865.58 |
| 递延所得税资产 | 23,122,209.06 | 23,313,537.59 | 25,556,141.18 | 23,448,007.44 |
| 其他非流动资产 | 22,716,204.17 | 32,024,801.44 | 59,513,760.73 | 1,862,787.46 |
| 非流动资产合计 | 1,999,952,713.05 | 1,866,866,814.42 | 1,749,277,632.52 | 1,701,668,689.5 |
| 资产总计 | 3,399,192,091.84 | 3,408,835,418.95 | 3,248,203,538.3 | 3,008,595,259.36 |
| 流动负债: | | | | |
| 短期借款 | 130,581,745.13 | 160,851,662.06 | 185,883,013.98 | 173,854,901.24 |
| 应付票据及应付账款 | 365,983,282.99 | 383,736,511.27 | 442,002,542.07 | 391,197,412 |
| 其中：应付票据 | 162,801,550.92 | 215,684,223.57 | 275,586,230.25 | 207,752,912.26 |
| 应付账款 | 203,181,732.07 | 168,052,287.7 | 166,416,311.82 | 183,444,499.74 |
| 合同负债 | 19,716,018.18 | 20,907,468.99 | 23,574,861.83 | 19,511,485.28 |
| 应付职工薪酬 | 29,354,770.42 | 23,913,593.51 | 20,518,444.23 | 30,539,231.87 |
| 应交税费 | 14,409,293.91 | 18,385,625.81 | 24,222,309.97 | 15,627,719.38 |
| 其他应付款合计 | 48,161,274.87 | 90,884,904.42 | 41,231,411.46 | 45,633,664.01 |
| 应付股利 | - | 40,627,191.4 | - | - |
| 一年内到期的非流动负债 | 39,929,381.16 | 41,318,749.23 | 16,012,711.11 | 30,025,544.44 |
| 其他流动负债 | 22,351,114.84 | 13,655,522.39 | 24,427,626.87 | 33,941,153.52 |
| 流动负债合计 | 670,486,881.5 | 753,654,037.68 | 777,872,921.52 | 740,331,111.74 |
| 非流动负债: | | | | |
| 长期借款 | 344,885,078 | 261,657,732 | 140,157,854.45 | 24,715,078 |
| 递延收益 | 61,425,808.91 | 63,453,802.46 | 57,744,290.23 | 52,568,950.29 |
| 递延所得税负债 | 2,541,921.79 | 2,628,265.97 | 2,714,610.16 | 2,800,954.32 |
| 其他非流动负债 | 750,000 | 1,750,000 | 1,750,000 | 1,750,000 |
| 非流动负债合计 | 409,602,808.7 | 329,489,800.43 | 202,366,754.84 | 81,834,982.61 |
| 负债合计 | 1,080,089,690.2 | 1,083,143,838.11 | 980,239,676.36 | 822,166,094.35 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 201,784,357 | 201,784,357 | 201,784,357 | 202,332,557 |
| 资本公积 | 1,440,227,393.04 | 1,439,677,349.62 | 1,439,095,470.41 | 1,451,418,977.2 |
| 减:库存股 | 31,473,490 | 30,855,345 | 1,295,976.4 | 18,085,589.88 |
| 其他综合收益 | -4,591,337.3 | -4,546,384.88 | -4,445,447.51 | -3,780,027.39 |
| 盈余公积 | 76,539,956.25 | 76,539,956.25 | 71,993,771.27 | 71,993,771.27 |
| 未分配利润 | 623,847,403.88 | 630,892,278.22 | 547,441,172.29 | 469,766,431.11 |
| 归属于母公司股东权益合计 | 2,306,334,282.87 | 2,313,492,211.21 | 2,254,573,347.06 | 2,173,646,119.31 |
| 少数股东权益 | 12,768,118.77 | 12,199,369.63 | 13,390,514.88 | 12,783,045.7 |
| 股东权益合计 | 2,319,102,401.64 | 2,325,691,580.84 | 2,267,963,861.94 | 2,186,429,165.01 |
| 负债和股东权益合计 | 3,399,192,091.84 | 3,408,835,418.95 | 3,248,203,538.3 | 3,008,595,259.36 |
| 公告日期 | 2026-10-23 | 2026-08-15 | 2026-04-28 | 2026-04-17 |
| 审计意见(境内) | | | | 标准无保留意见 |